Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
humanized monoclonal antibody being investigated for the prevention of respiratory syncytial virus infection in high-risk infants.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word motavizumab.
Examples
-
According to the lawsuit, filed Aug. 21 in U.S. District Court, Abbott had a deal to develop and market a new drug called motavizumab in countries outside the U.S. The drug was to be a successor to an earlier respiratory drug developed by Gaithersburg-based MedImmune called Synagis which has millions of dollars in sales in the U.S. alone.
unknown title 2011
-
halted further development in December of its next-generation vaccine to prevent RSV - a product called motavizumab that was meant to replace its blockbuster-selling Synagis drug.
Novavax starts RSV clinical trials | Washington Business Journal 2011
-
The discontinuation of motavizumab changes the playing field in this potentially lucrative area, and makes Alnylam Pharmaceuticals Inc. and Cubist Pharmaceuticals Inc.'s ALN-RSV01, currently in Phase II development, the most advanced RSV therapy in de velopment.
-
AstaZeneca said on Tuesday that it is halting development of its pediatric respiratory drug motavizumab.
Stocks Keep The Santa Spirit For The Week MarketNewsVideo.com 2010
-
AstraZeneca said it halted the development of the drug motavizumab for the prevention of a respiratory infection, resulting in a $445 million impairment charge in the fourth quarter.
Business Watch 2010
-
The company said motavizumab remains in development for other respiratory syncytial-virus treatment.
Astra Limits Respiratory Drug's Development Patricia Kowsmann 2010
-
LONDON — AstraZeneca PLC said Tuesday that it has halted the development of the drug motavizumab for the prevention of a respiratory infection, resulting in a $445 million impairment charge in the fourth quarter.
Astra Limits Respiratory Drug's Development Patricia Kowsmann 2010
-
Berenberg Bank analyst Alistair Campbell said motavizumab wasn't "mission critical" for AstraZeneca since MedImmune already made a similar product that is sold as Synagis.
Astra Limits Respiratory Drug's Development Patricia Kowsmann 2010
-
AstaZeneca AZN said today it is halting development of its pediatric respiratory drug motavizumab.
-
AstaZeneca AZN said today it is halting development of its pediatric respiratory drug motavizumab.
Forbes.com: News MarketNewsVideo.com 2011
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.